Clinical Trials Browser

Withdrawn × tremelimumab × Thoracic × Clear all

NCT04625699 2023-06-06

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03319316 2022-01-10

SOLUTION

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

NCT03130764 2017-12-06

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung